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I.   Abstract 
 
MicroRNA 122 (MiR-122) is an abundant liver-specific miRNA which serves to regulate 
hepatic metabolism, and functions as a tumor suppressor. We are determining how a tiny, 
twenty-two nucleotide microRNA maintains homeostatic liver function. Loss of hepatic 
phenotype, metastasis, and poor prognosis are characteristics of down regulation of miR-122 
expression. Spontaneous Hepatocellular Carcinoma (HCC) development has been observed in 
liver-specific (LKO) and germ-line (KO) knockout miR-122 mice. Results of Ago-HITS-CLIP 
analysis conducted in livers of 6 week-old wild type and KO mice confirmed ~1800 miR-122 
binding sites present in wild-type, but absent in KO livers. MiR-122 binding sites were identified 
on the 3’ untranslated regions (3’-UTR) of the snail family zinc finger 2 (Snai2) gene, TIMP 
metallopeptidase inhibitor 2 (Timp2) gene, LIM domain kinase 1 (Limk1) gene, Hepatocyte 
Nuclear Factor 4 alpha (Hnf4a) and Pygopus Family PHD Finger 2 (Pygo2). 	  
The encoded protein of Snai2 is involved in epithelial mesenchymal transitions, and has 
the ability to enable the cell to resist apoptotic signals. Timp2 functions as a metastasis 
suppressor. Limk1 regulates actin polymerization through phosphorylation and subsequent 
inactivation of cofilin, while Hnf4a regulates liver development. Pygo2 is involved in signal 
transduction of the Wnt and GPCR pathways. The presence of these discovered binding sites 
highly suggests targeting and regulation by miR-122. These genes are potentially involved in 
liver pathogenesis, and could be crucial with respect to determining HCC progression. To 
explore the possibility of targeting and regulation by miR-122, real-time reverse-transcription 
polymerase chain reaction (qRT-PCR) was conducted.  We hypothesized that in the absence of 
miR-122, expression levels of these genes would be increased. These five targets were found to 
be highly expressed in miR-122 knockout mice. RNA-sequencing analysis suggests that these 
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genes are undergoing regulation by miR-122. Snai2 has been validated as a direct miR-122 target 
using luciferase assay technology with hepatoma (Hepa) cells. Snai2 has been further validated 
using site-directed mutagenesis in Hepa cells. Broader implications of this study include miR-
122 itself or Snai2 being targeted for HCC therapy in human patients. 
 
II.   Background  
 
MicroRNAs (miRNAs) are short, noncoding RNAs composed of approximately 22 
nucleotides that serve to negatively regulate protein-coding genes [1]. Following their 
transcription into hairpin pri-microRNAs in the nucleus, they are then cleaved to their pre-
microRNA forms. Exportin proteins in combination with RAN-GTP allow for RNA nuclear 
export into the cytoplasm, where the pre-microRNA is again cleaved by Dicer, and the 5’ strand 
is uploaded to the RNA-induced silencing complex (RISC) in conjunction with Argonaute 2 
proteins [1]. After undergoing processing in the RISC complex, the microRNA is now mature 
and ready to conduct its cellular functions, such as mRNA target cleavage, translational 
repression and/or mRNA adenylation (Figure 1).  
In liver development, miRNAs are known to be important in cell differentiation as well as 
organ development [1]. MicroRNA-122 (miR-122) is essential for maintenance of liver 
homeostasis, and is conserved across vertebrate species [2,3,4]. Its complete conservation 
reflects its critical role in the liver. As the most abundant liver-specific miRNA, it accounts for 
70% of total liver microRNA as demonstrated when cloning varying mouse tissue miRNA.  
MiR-122 serves to regulate a variety of diverse functions. These include glucose homeostasis, 
lipid metabolism, and cholesterol [2,3]. It has also been shown to promote hepatitis C virus 
(HCV) replication [2]. Its inhibition results in dysregulation of hepatic lipid metabolism and iron 
homeostasis [4]. While miR-122 is not necessary for embryogenesis in mice (as demonstrated by 
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successful generation of germ-line knockout mice), complete loss of miR-122 results in 
spontaneous steatohepatitis early in life and hepatocellular carcinoma (HCC) with age [3,4].  
Additionally, studies show that ectopic expression of miR-122 in both human and mouse stem 
cells results in differentiation into hepatocyte-like cells in vitro. This suggests that depletion of 
miR-122 levels in humans may also have severely negative consequences in humans [3]. Loss of 
miR-122 also results in upregulation of its target genes, while its overexpression in HCC cell 
lines reduces tumerigenesis [2]. Ultimately, miR-122’s roles as a tumor suppressor and master 
regulator of other protein-coding genes, along with its specificity to the liver makes it an 
attractive target for gene therapy, both as a mimic and anti-miRNA. It also serves as a key 
prognostic marker in identifying patients with advanced hepatocellular carcinoma (HCC) [4].  
Located on chromosome 18, miR-122 is first transcribed as an approximately 7.5 
kilonucleotide primary transcript from an intergenic region [2]. It is then processed to a 66 
nucleotide precursor RNA, which is then spliced to a tiny, 22 nucleotide mature miR-122. It is 
stabilized by the addition of a single adenosine to it’s 3’ –end by GLD2, a noncanonical 
cytoplasmic poly(A) polymerase. This stabilization is thought to be the cause of miR-122 
abundance [4]. Mature miR-122 interacts with its target mRNAs through binding at a variety of 
seed sites, located on its 3’UTR (Figure 2).   
 HCC is the most common occurring liver cancer, and is the fifth most prevalent cancer in 
the world [2]. It serves as the third leading cause of cancer related deaths, and its incidence has 
nearly tripled in the United States over the past 20 years [5]. HCC often arises in patients 
experiencing chronic liver disease, cirrhosis, and inflammation. Both alcoholic and non-alcoholic 
fatty liver disease promote HCC development. Other primary risk factors for HCC include 
hepatitis B and C virus infections, as well as genetic mutations [4]. Reduced miR-122 expression 
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is associated with spontaneous development of HCC, and correlates with poor prognosis and 
metastasis in human HCC patients [6]. Few therapies exist to treat HCC, and since early 
diagnosis of HCC is difficult to achieve, HCC mortality rates continue to steadily rise [4]. The 
disease is so progressive that death usually occurs within 10 months of initial diagnosis [7]. 
Therefore, investigation of specific genetic alterations is vital to the pursuit of novel HCC 
therapies. 
 Gene therapy has been utilized to treat human patients with HCC to restore homeostatic 
liver function and normal gene expression. While siRNA-mediated silencing of a disease-causing 
target gene serves as a potential option, it is likely that redundant genes possessing 
complementary functions could compensate the function of a knockdown gene. Many studies 
relating microRNAs to a specific disease are centered on identifying and validating candidate 
target genes as predicted by different databases [3]. This is a necessary step prior to evaluating 
the biological functions of target genes and eventual development of gene-specific therapies for 
clinical trials.  
 The snail family zinc finger 2 (Snai2) gene encodes for a zinc finger transcription factor 
that represses transcription through binding to E-box consensus elements. Snai2 can activate its 
own expression through binding to E-box elements in the binding regions of its own promoter 
[8,9]. Structurally, it possesses five zinc fingers in its C-terminal domain which interact with the 
canonical E box sequence [9,10,11]. It has previously been found to be overexpressed in many 
cancers, including lung, esophageal, colorectal, gastric, pancreatic, breast, prostate, ovarian, 
leukemia, and glioma. Its overexpression is described as a hallmark of epithelial mesenchymal 
transition (EMT), and low survival [10,11]. EMT occurs during adult wound healing as well as 
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cancer metastases [10]. The process involves a decrease in expression of cell junction 
components, resulting in a motile and invasive mesenchymal phenotype.  
 Timp2 was recently discovered to be the most significantly downregulated member of the 
TIMP gene family in human HCCs. Additionally, it was found that stable silencing of Timp2 in 
HCC cell lines enhanced cell invasiveness. In xenograft mouse models, it was demonstrated that 
ectopic expression of Timp2 in the HCC cell line MHCC-97L significantly reduced HCC 
progression and metastasis [12]. Findings from this same paper further established that Timp2 is 
an important regulator of extracellular matrix degradation [12]. These newfound discoveries are 
indicative that Timp2 is heavily involved with HCC progression.  
 Increased expression levels of LIMK1 are correlated with tumor differentiation, cell 
invasiveness, cell motility, and poor patient prognosis [13,14]. As a serine/threonine protein 
kinase, it plays a crucial role in regulating dynamics of actin filaments. LIMK1 inhibitors have 
additionally been used to block tumor cell proliferation by disrupting mitotic microtubule 
organization in kidney cancer cells [15]. Hnf4a regulates epithelial cell function, and functions as 
a nuclear transcription factor [17]. Pygo2 functions in the high-conserved Wnt/B-catenin 
signaling pathway, and has additionally served as a prognostic marker for glioma [18].  
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III. Materials and Methods 
1. HITS-CLIP  
High-Throughput sequencing with cross-linking and immunoprecipitation with the 
Argonaut protein complex(Ago-HITS-CLIP) was used to determine sites on mRNAs believed to 
be miR-122 targets. This technique was originally developed as a means of further understanding 
how protein-RNA complexes interaction regulate gene expression in living cells [19,20]. Ago-
HITS-CLIP allows for a genome-wide screen of RNA binding sites in vivo. Following UV 
irradiation of mouse liver samples, the cells underwent lysis, partial RNase digest, and 
immunoprecipitation (Figure 3).   
Argonaute proteins bind different classes of small, non-coding RNAs. By measuring 
argonaute pull-down of miR-122 specific seed sites, Ago-HITS-CLIP thus also measures the 
binding of miR-122 to target genes containing the miR-122 binding site. MiR-122 binding is 
visualized in the form of peaks on a graph (Figure 4). In wild-type mice, pull-down of genes with 
the specific miR-122 binding sites will occur. This is because miR-122 is present in these mice, 
and thus can bind to its respective target genes. Ago-HITS-CLIP data will register a peak at 
those regions.  
 In miR-122 KO mice, there will be significantly less or complete lack of pull 
down of miR-122 sequence-specific gene regions by the Argonaute protein complex. This is 
because miR-122 is absent from these mice, and thus cannot bind to its complementary sites of 
target genes. This will cause the peaks shown on HITS-CLIP data to disappear  
The differences in occurring peaks shown on HITS-CLIP data from wild-type and KO 
mice were used to determine the likelihood of miR-122 regulation. Additionally, we ensured the 
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peak region contained the miR-122 seed site (CACTCC) and confirmed that the Snai2 region 
was conserved in humans (Figure 5).  The miR-122 binding site appears as a 7A1mer in mice 
and as a 6mer in humans (refer to figure 2 for specific seed sequences). 
 
2. RNA-Sequencing 
RNA-sequencing (RNA-seq) was used to measure relative gene expression of wild-type 
mice versus miR-122 KO mice. This assay measures the number of mRNA reads for a multitude 
of genes, both known and unknown, in wild-type and KO mice. We are particularly interested in 
the predicted target genes of miR-122. This assay served as a validation strategy to determine the 
mRNA level of miR-122 targets and in-vivo function of miR-122. The relative gene expression 
was calculated by taking the log of the ratio of wild-type mRNA reads/KO mRNA reads (Table 
1). It was predicted that KO mice would contain more mRNA reads of suspected target genes 
because miR-122 was not present to regulate those genes. Thus, it was also thought that 
prospective targets of miR-122 would have WT/KO mRNA read ratios of less than 1. The logs 
of these values would then be negative, indicative of relative fold change.  
 A comparison of RNA-seq data and Ago-HITS-CLIP data results in an inverse 
relationship in terms of the peaks which register on the raw data. MiR-122 target genes in RNA-
seq will demonstrate a peak, while miR-122 target genes defined by Ago-HITS-CLIP will not 
register a peak (Figure 6). This peak comparison between the two data set is what allowed us to 
identify particular targets.  
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3. qRT-PCR analysis of miR-122 targets in liver RNA isolated from the wild type and KO 
Mouse cDNA 
Mouse RNA was extracted from miR-122 KO mice using TRIZol (Life Technologies, 
Inc).  2 ug of RNA was converted to cDNA (Bioline). The reaction was conducted at 
25°C for 10 minutes, 37°C for 2 hours, and 85°C for 5 minutes. Samples were treated 
with with DNaseI to remove residual DNA copurified with RNA. SYBR Green 
fluorescent dye, 3’UTR Snai2 specific primers, and the newly-made cDNA was then 
utilized in qRT-PCR. Housekeeping gene GAPDH (involved in catalyzing glucose 
breakdown) was used as a normalizer. 
 
4.   3’UTR Amplification, Isolation, and Purification  
Polymerase Chain Reaction was conducted with Accuprime Polymerase and dNTPs 
to amplify the 3’UTR regions of mouse Snail2, Timp2, and Hnf4a. The PCR was run for 
27 cycles of 30 sec at 94°C, 30 seconds at 56°C, and 30 seconds at 68°C. DNA loading 
buffer 6X was added to the PCR product and the DNA was run on a 1.5% agarose gel 
(1.5g agarose/ 100 mL 1X Tris-Acetate EDTA Buffer) containing ethidium bromide at 80 
V for 45 minutes. The PCR product was run alongside a 100 bp ladder to ensure the 
product was the correct size. The band was then visualized with ultraviolet light, and cut 
from the gel with a razor. Remaining agarose along with other impurities were removed 
from the PCR product using QIAquick Gel Extraction Kit according to the 
manufacturer’s instructions.  Approximately 450 ng of product was digested overnight at 
37°C with restriction enzymes Not I and Xho I. 50 ng of psiCHECK2 was simultaneously 
digested under the same conditions in preparation for ligation of the 3’UTR sequence into 
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the psiCHECK2 vector.  The 3’UTR PCR product was purified using Qiagen PCR 
Purification Kit following the manufacturers instructions.  
 
a.   Vector Ligation  
50 ng of psiCHECK2 (Figure 7) were combined with approximately 10 ng of the 
digested 3’UTR gene insert. 1 uL of 10X QuickLigase and 5 uL of 2X Ligase Buffer 
were added to the reaction, and the reaction was incubated at 25°C for 30 minutes.  
 
b.   Transformation  
Clones were amplified by transforming the newly-ligated constructs into 
competent DH5α cells. DH5α cells were thawed on ice for 15 minutes. 25 uL of cells 
were combined with 10uL of freshly ligated plasmid. The plasmid was added to the cells 
to reduce cellular damage.  The mixture was chilled on ice for 30 minutes prior to 
undergoing a heat shock at 37°C for 2 minutes. The mixture of cells and plasmid was 
then chilled on ice for 5 minutes. After addition of 0.5 mL of pure Luria-Bertani broth 
(LB), the cells were rocked at 37°C and 75 rpm for 1 hour.  Cells were pelleted via 
centrifuge (5k rpm), and resuspended in 100 uL of media. The cell solution was spread 
on a sterile LB plate containing ampicillin. Bacterial colonies were grown for 16 hours at 
37°C. Individual colonies were tested by PCR to identify positive clones (harboring 
specific 3’UTRs), allowed to grow in LB- ampicillin medium and plasmid DNAs of the 
cultures was purified using QIAprep Miniprep Kit. The recombinant psiCHECK2 DNAs 
were screened by digesting with Xho I and Not I followed by gel electrophoresis.  Sanger 
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Sequencing confirmed that the vector contained the Snai2 sequence with the miR-122 
binding site.  
 
4. Transfection with psiCHECK2 Snai2  
Transfection was conducted in the following manner with additional genes of Hnf4a and 
Timp2.  
 Mouse Hepa cells were seeded into 16 wells of a 24-well-plate (1.2 million cells/well). 
Next day, cells were transfected with 100 ng of the psicheck2-Snai2 vector in both the presence 
of 5 uM of miR-122 mimic as well as 5 uM of NC RNA (scrambled RNA). Additional Hepa 
cells were transfected simultaneously with 200 ng of psicheck2 to act as a control both the 
presence of 5 uM of miR-122 mimic as well as 5 uM of NC RNA (Figure 8). The transfection 
was performed in Minimum Essential Media (MEM) (Eagle) containing 10% (55 mL) Fetal 
Bovine Serum, 1.0% sodium pyruvate, 1.0% nonessential amino acids, and 1.0% Penicillin 
Streptomycin (for prevention of bacterial infection). Lipofectamine 3000 and p3000 (Invitrogen) 
reagents with optiMEM media (ThermoFisher Scientific) were utilized in the transfection 
according to the manufacturer’s protocol. The Lipofectamine serves to form lipid complexes 
around the cloned vectors containing the gene of interest, and thus allows the vector to penetrate 
the double-layered lipid bilayer of the cell membrane. The reaction took place over a period of 6 
hours at 37°C. Following the reaction, media was replaced with 600 uL of MEM. Cells were 
incubated for approximately an additional 24 hours at 37°C. Cells were washed twice with 
Phosphate-buffered saline (PBS) before lysis. Cell contents were transferred to individual 
Eppendorf tubes for further use in luciferase assay.  
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5. Luciferase Assay 
 Cell lysate was centrifuged for 5 minutes at 13200 RPM to pellet cell debris. 
MicroWin2000 machine was prepared via a washing with distilled water, and primed with 
luciferase assay reagents StopNGlo and Lar2. 10 uL of each cell lysate sample was loaded into a 
well of an opaque 96-well-plate. Analysis of the data was conducted by comparing differences 
between Snai2 transfected cells in the presence of miR-122 mimic versus in the presence of 
scrambled RNA negative control.  
 
6. Site-Directed Mutagenesis  
 New 3’ UTR primers were generated to mutate miR-122 binding site in the 3’-UTR of 
Snai2 using MacVector following published protocol  [2]. The new primer sequences contain 
mutated base pairs relative to the primer sequences utilized in generating the original Snai2-
psicheck2 vector (Table 2). 3’UTR amplification was performed in three steps with the new 
primers using Accuprime polymerase (Invitrogen) and dNTPs. The first PCR amplification step 
involved utilizing the forward site-directed mutagenesis primer with the original reverse 3’UTR 
primer. PCR was performed again using the original forward primer and the site-directed 
mutagenesis reverse primer. The PCR products from these two reactions were combined, and 
amplified using both the forward and reverse original primers to obtain the desired product 
containing a mutated miR-122 binding site. Plasmid isolation and purification, along with 
Transformation, Transfection, and Luciferase Reporter Assay were performed in the same 
fashion as with the original Snai2-psicheck2 vector.  
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IV. Results 
 Ago-HITS-CLIP and RNA-seq analysis indicated that Snai2, Limk1, Hnf4a, Pygo2, and 
Timp2 are targets of miR-122 (Table 1).  A standard 2-tailed t-test was used to assess both qRT-
PCR and Luciferase Reporter Assay data. A p-value of less than 0.05 was used to determine if 
the data gathered was significant. Real-time RT-PCR also indicated that these five genes were 
targets of miR-122 (Figures 9-12). Luciferase Reporter Assay analysis indicated that Snai2 is a 
direct target of miR-122, and site-directed mutagenesis confirmed Snai2 as a miR-122 target 
(Figures 13 and 14). Luciferase Reporter Assay analysis of Hnf4a and Timp2 produced negative 
data (p > 0.05) that could not confirm that these genes are miR-122 targets (Figures 15 and 16). 
This could be due to miR-122 having a higher binding affinity in vivo than when miR-122 target 
genes are associated with its own coding sequence instead of ligated to transgenes such as 
Luciferase. Also compared to 8mer and 7 mer miR-122 binding sites, 6mer binding sites have 
lower affinity that may not be strong enough to reduce luciferase expression. For future potential 
miR-122 targets, I would plan to investigate target genes of miR-122 as predicted by Ago-HITS-
CLIP and RNA-seq that contained miR-122 8 or 7mer binding sites on their 3’UTRs.  
 
V. Discussion and Final Conclusions  
Before I contributed to the primary research goals in Dr. Ghoshal’s laboratory, many 
potential miR-122 targets were still being investigated. Several genes had neither been confirmed 
or unconfirmed as direct targets, and little was known about the relationship between Snai2 and 
miR-122. Over time in the lab, I have greatly contributed to our laboratory’s larger goal of 
determining miR-122 canonical pathways through extensive genotyping of mice to identify WT 
and KO mice, those were used for Ago-HiTS-CLIP analysis. I confirmed that Snail2 is a direct 
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target of miR-122. Because of my efforts, more is known about what genes are and are not 
targeted by master regulator miR-122 in liver carcinoma.  
 This research has extensive future implications. Gene therapy for cancer patients in 
becoming a more commonplace and effective method of treating cancer. Currently with only one 
available FDA-approved therapy for advanced stages of HCC, there is a clinical need for further 
treatment options. The current available therapy, sorafenib, is a multikinase inhibitor. While this 
treatment does provide minimal survival benefit for advanced HCC patients, the side effects are 
severe. A 2009 study produced data that did not support the use of sorafenib in patients. In our 
lab, it was previously demonstrated that miR-122 sensitizes HCC cells to sorafenib and that the 
cells have reduced malignant properties [7]. Previously in our lab it was demonstrated that 
delivery of the miR-122 minigene to mice containing a tetracyclin-repressible MYC transgene 
using a self-complementary adenoassociated virus (scAAV) resulted in dramatic inhibition of 
liver tumor growth [2] (Figure 17). Potentially in the future, therapeutic drugs could be 
developed to correct either low miR-122 expression levels, that may inhibit Snai2 to block EMT 
and metastasis.  Transcription factors, in general, are not targetable using small molecule 
inhibitors. Thus, HCC expressing high levels of Snai2 could potentially be treated with miR-122. 
As a transcription factor, Snai2 is thought to possess several direct targets itself, such as 
transmembrane adhesion molecule E-cadherin [10]. Since this E-cadherin is a vital molecule in 
cell-cell adhesion and has already been shown on several occasions to increase proliferation and 
metastasis, its deregulation in conjunction with Snai2’s deregulation by miR-122 poses an 
interesting path in examining Snai2’s targets, along with its direct role in EMT and liver 
carcinogenesis.   
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Figure	  3:	  Ago-­‐HITS-­‐CLIP	  mechanism	  for	  detecting	  in-­‐vivo	  
microRNA	  binding	  	  
Moore	  MJ	  et	  al,	  Nature	  Protocols.	  2014 
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Figure	  4:	  Ago-­‐HITS-­‐CLIP	  data	  shows	  peak	  present	  in	  location	  specific	  to	  miR-­‐122.	  More	  
pull-­‐down	  of	  miR-­‐122	  target	  gene	  sequences	  by	  the	  Argonaut	  protein	  will	  lead	  to	  
occurring	  peaks	  in	  miR-­‐122	  KO	  mice.	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